750
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

, , &
Pages 494-502 | Received 05 Feb 2015, Accepted 01 May 2015, Published online: 03 Jun 2015

References

  • WHO . Report of the advisory committee on health research. Geneva: Genomics and World Health; 2002
  • Tunstall- Pedoe H , Tunstall-Pedoe H . Preventing chronic diseases. A Vital investment: WHO global report. World Health Organization, Geneva; 2005. pp 200. Available from http://www.who.int/chp/chronic_disease_report/en/. Int J Epidemiol 2006;35(4):1107
  • Vasant H . Adult anthropometric measures, overweight and obesity. In Health Survey for England. Volume 1. Adult anthropometric measures, overweight and obesity In Health Survey for England. Health Social Care Heath Centre 2010
  • Bridges ST . Children’s BMI, overweight and obesity. Health Survey Engl 2010
  • Flegal KM , Carroll MD , Kit BK , Ogden CL . Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491–7
  • Ogden CL , Carroll MD , Kit BK , Flegal KM . Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483–90
  • Fried M , Yumuk V , Oppert JM , Scopinaro N , Torres A , Weiner R , et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg 2014;24:42–55
  • Swinburn BA , Sacks G , Hall KD , McPherson K , Finegood DT , Moodie ML , Gortmaker SL . The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378:804–14
  • Johansson K , Sundström J , Marcus C , Hemmingsson E , Neovius M . Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obesity 2014;38:279–84
  • Tsai AG , Wadden TA . The evolution of very-low-calorie diets: an update and meta-analysis. Obesity 2006;14:1283–93
  • Avenell A , Brown TJ , McGee MA , Campbell MK , Grant AM , Broom J , et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Human Nutr Diet 2004;17:317–35
  • Malik VS , Hu FB . Popular weight-loss diets: from evidence to practice. Nat Clin Pract Cardiov Med 2007;4:34–41
  • Bazzano LA , Hu T , Reynolds K , Yao L , Bunol C , Liu Y , et al. Effects of Low-Carbohydrate and Low-Fat Diets. Ann Int Med 2014;161:309
  • Sacks FM , Bray GA , Carey VJ , Smith SR , Ryan DH , Anton SD , et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Eng J Med 2009;360:859–73
  • Johnston BC , Kanters S , Bandayrel K , Wu P , Naji F , Siemieniuk RA , et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA 2014;312:923
  • Wing RR , Lang W , Wadden TA , Safford M , Knowler WC , Bertoni AG , et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–6
  • Lim EL , Hollingsworth KG , Aribisala BS , Chen MJ , Mathers JC , Taylor R . Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506–14
  • Damms-Machado A , Weser G , Bischoff SC . Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J 2012;11:34
  • Curioni CC , Lourenço PM . Long-term weight loss after diet and exercise: a systematic review. Int J Obesity 2005;29:1168–74
  • Douketis JD , Macie C , Thabane L , Williamson DF . Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obesity 2005;29:1153–67
  • Dansinger ML , Gleason JA , Griffith JL , Selker HP , Schaefer EJ . Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43–53
  • Keys A . Human starvation and its consequences. J Am Diet Assoc 1946;22:582–7
  • Lomer M . Advanced Nutrition and dietetics in Gastroenterology. Wiley Blackwell, West Sussex, UK; 2014
  • Sumithran P , Prendergast LA , Delbridge E , Purcell K , Shulkes A , Kriketos A , Proietto J . Long-term persistence of hormonal adaptations to weight loss. N Eng J Med 2011;365:1597–604
  • Ebbeling CB , Swain JF , Feldman HA , Wong WW , Hachey DL , Garcia-Lago E , Ludwig DS . Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012;307:2627–34
  • Leibel RL , Rosenbaum M , Hirsch J . Changes in energy expenditure resulting from altered body weight. N Eng J Med 1995;332:621–8
  • Camps SG , Verhoef SP , Westerterp KR . Weight loss, weight maintenance, and adaptive thermogenesis 1-3. Am J Clin Nutr 2013;97:990–5
  • Ochner CN , Barrios DM , Lee CD , Pi-Sunyer FX . Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav 2013;120:106–13
  • Rosenbaum M , Sy M , Pavlovich K , Leibel RL , Hirsch J . Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Investig 2008;118:2583–91
  • Hinkle W , Cordell M , Leibel R , Rosenbaum M , Hirsch J . Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One 2013;8:e59114
  • Catenacci VA , Wyatt HR . The role of physical activity in producing and maintaining weight loss. Nat Clin Pract Endocrinol Metabol 2007;3:518–29
  • Tate DF , Jeffery RW , Sherwood NE , Wing RR . Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain? Am J Clin Nutr 2007;85:954–9
  • NICE guidelines [CG189] . Obesity: identification, assessment and management of overweight and obesity in children, young people and adults 1-recommendations Guidance and guidelines. 2014
  • Physical Activity Guidelines for Americans . 2008. Available from: http://www.health.gov/paguidelines/guidelines/chapter4.aspx
  • Trost SG , Owen N , Bauman AE , Sallis JF , Brown W . Correlates of adults’ participation in physical activity: review and update. Med Sci Sports Exercise 2002;34:1996–2001
  • Jensen MD , Ryan DH , Apovian CM , Ard JD , Comuzzie AG , Donato KA , et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol 2014;63:2985–3023
  • Kayman S , Bruvold W , Stern JS . Maintenance and relapse after weight loss in women: behavioral aspects. Am J Clin Nutr 1990;52:800–7
  • WHO . Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. WHO Technical. World Health Organization, Geneva; 2000. Available from http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/
  • NIH conference . Gastrointestinal surgery for severe obesity. consensus development conference panel. Ann Int Med 1991;115:956–61
  • Busetto L , Dixon J , De Luca M , Shikora S , Pories W , Angrisani L . Bariatric surgery in class I obesity: a position statement from the international federation for the surgery of obesity and metabolic disorders (IFSO). Obes Surg 2014;24:487–519
  • Angrisani L , Santonicola A , Iovino P , Formisano G , Buchwald H , Scopinaro N . Bariatric Surgery Worldwide 2013. Obesity Surgery 2015. [Epub ahead of print]
  • Slater GH , Ren CJ , Siegel N , Williams T , Barr D , Wolfe B , et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastroint Surg 2004;8:48–55; discussion 54–5
  • Aasheim ET , Bjo S , Hanvold SE , Engström M , Hanvold SE , Mala T , et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch 1 – 3. Am J Clin Nutr 2009;90:15–22
  • Buchwald H , Estok R , Fahrbach K , Banel D , Jensen MD , Pories WJ , et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56
  • Pournaras DJ , Aasheim ET , Søvik TT , Andrews R , Mahon D , Welbourn R , et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 2012;99:100–3
  • Mingrone G , Panunzi S , De Gaetano A , Guidone C , Iaconelli A , Leccesi L , et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Eng J Med 2012;366:1577–85
  • Sjöström L . Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–34
  • Trastulli S , Desiderio J , Guarino S , Frampton GK . Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surgery Obesity Related Dis 2013;9:816–29
  • Wang MC , Guo XH , Zhang YW , Zhang YL , Zhang HH , Zhang YC . Laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy for obese patients with Type 2 diabetes: a meta-analysis of randomized controlled trials. Am Surg 2015;81:166–71
  • Diamantis T , Apostolou KG , Alexandrou A , Frampton GK . Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surgery Obesity Related Dis 2014;10:177–83
  • Schauer PR , Bhatt DL , Kirwan JP , Wolski K , Brethauer SA , Navaneethan SD , et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Eng J Med 2014;370:2002–13
  • Dirksen C , Jørgensen NB , Bojsen-Møller KN , Jacobsen SH , Hansen DL , Worm D , et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012;55:1890–901
  • Cummings DE , Overduin J , Shannon MH , Foster-Schubert KE . Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Sur Obesity Relat Dis 2005;1:358–68
  • Cummings DE , Weigle DS , Frayo RS , Breen PA , Ma MK , Dellinger EP , Purnell JQ . Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Eng J Med 2002;346:1623–30
  • Borg CM , le Roux CW , Ghatei MA , Bloom SR , Patel AG , Aylwin SJ . Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210–15
  • Le Roux CW , Welbourn R , Werling M , Osborne A , Kokkinos A , Laurenius A , et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780–5
  • Roux CW , Aylwin SJ , Batterham RL , Borg CM , Coyle F , Prasad V , et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108–14
  • Näslund E , Backman L , Holst JJ , Theodorsson E , Hellström PM . Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obesity Surg 1998;8:253–60
  • MacDonald PE , El-kholy W , Riedel MJ , Salapatek AM , Light PE , Wheeler MB . The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51:S434–42
  • Verdich C , Flint A , Gutzwiller JP , Näslund E , Beglinger C , Hellström PM , et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382–9
  • Cohen MA , Ellis SM , Le Roux CW , Batterham RL , Park A , Patterson M , et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696–701
  • Batterham RL , Cohen MA , Ellis SM , Le Roux CW , Withers DJ , Frost GS , et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Eng J Med 2003;349:941–8
  • Wynne K , Park AJ , Small CJ , Meeran K , Ghatei MA , Frost GS , Bloom SR . Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obesity 2006;30:1729–36
  • Fenske WK , Bueter M , Miras a D , Ghatei MA , Bloom SR , le Roux CW . Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obesity 2012;36:379–84
  • Falkén Y , Hellström PM , Holst JJ , Näslund E . Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: Role of gut peptides. J Clin Endoc Metab 2011;96:2227–35
  • Dirksen C , Jørgensen NB , Bojsen-Møller KN , Kielgast U , Jacobsen SH , Clausen TR , et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obesity 2013;37:1452–9
  • Jiménez A , Casamitjana R , Viaplana-Masclans J , Lacy A , Vidal J . GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013;36:2062–9
  • Mokadem M , Zechner JF , Margolskee RF , Drucker DJ , Aguirre V . Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 2014;3:191–201
  • Jørgensen NB , Dirksen C , Bojsen-møller KN , Jacobsen SH , Worm D , Hansen DL , et al. Exaggerated glucagon-like peptide 1 response is important for improved b-cell function and glucose tolerance after roux-en-y gastric bypass in patients with type 2 diabetes. 2014;62:3044–52
  • Gribble FM . The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc 2012;71:456–62
  • Hao Z , Townsend RL , Mumphrey MB , Patterson LM , Ye J , Berthoud HR . Vagal innervation of intestine contributes to weight loss After Roux-en-Y gastric bypass surgery in rats. Obesity Surg 2014;24:2145–51
  • Gautron L , Zechner JF , Aguirre V . Vagal innervation patterns following Roux-en-Y gastric bypass in the mouse. Int J Obesity 2013;37:1603–7
  • Le Roux CW , Neary NM , Halsey TJ , Small CJ , Martinez-Isla AM , Ghatei MA , et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005;90:4521–4
  • Werling M , Vincent RP , Cross GF , Marschall HU , Fändriks L , Lönroth H , et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 2013;48:1257–64
  • Peterli R , Steinert RE , Woelnerhanssen B , Peters T , Christoffel-Courtin C , Gass M , et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obesity Surg 2012;22:740–8
  • Pournaras DJ , Glicksman C , Vincent RP , Kuganolipava S , Alaghband-Zadeh J , Mahon D , et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012;153:3613–19
  • Li JV , Ashrafian H , Bueter M , Kinross J , Sands C , le Roux CW , et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 2011;60:1214–23
  • Liou AP , Paziuk M , Luevano JM , Machineni S , Turnbaugh PJ , Kaplan LM . Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41
  • Sweeney TE , Morton JM . Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol 2014;28:727–40
  • Laferrère B , Teixeira J , McGinty J , Tran H , Egger JR , Colarusso A , et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479–85
  • Korner J , Inabnet W , Febres G , Conwell IM , McMahon DJ , Salas R , et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obesity 2009;33:786–95
  • Olbers T , Björkman S , Lindroos A , Maleckas A , Lönn L , Sjöström L , Lönroth H . Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006;244:715–22
  • Scholtz S , Miras AD , Chhina N , Prechtl CG , Sleeth ML , Daud NM , et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut 2014;63:891–902
  • Buchwald H , Estok R , Fahrbach K , Banel D , Sledge I . Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007;142:621–32
  • Dixon JB , Zimmet P , Alberti KG , Rubino F . Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabetic Med 2011;28:628–42
  • Jackson TD , Zhang R , Glockler D , Pennington J , Reddigan JI , Rotstein OD , et al. Health inequity in access to bariatric surgery: a protocol for a systematic review. System Rev 2014;3:15
  • Ahmad A , Laverty AA , Aasheim E , Majeed A , Millett C , Saxena S . Eligibility for bariatric surgery among adults in England: analysis of a national cross-sectional survey. JRSM open 2014;5:2042533313512479
  • European Medicines Agency . Draft Guideline on clinical evaluation of medicinal products used in weight control. 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170278.pdf
  • Colman E . Food and drug administration’s obesity drug guidance document: a short history. Circulation 2012;125:2156–64
  • James WP , Caterson ID , Coutinho W , Finer N , Van Gaal LF , Maggioni AP , et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Eng J Med 2010;363:905–17
  • Samat A , Tomlinson B , Taheri S , Thomas GN . Rimonabant for the treatment of obesity. Recent Patents Cardiov Drug Discov 2008;3:187–93
  • Li Z , Maglione M , Tu W , Mojica W , Arterburn D , Shugarman LR , et al. Meta-analysis: pharmacologic treatment of obesity. Ann Int Med 2005;142:532–46
  • Torgerson JS , Hauptman J , Boldrin MN , Sjöström L . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61
  • Colman E , Golden J , Roberts M , Egan A , Weaver J , Rosebraugh C . The FDA’s assessment of two drugs for chronic weight management. N Eng J Med 2012;367:1577–9
  • Smith SR , Weissman NJ , Anderson CM , Sanchez M , Chuang E , Stubbe S , et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Eng J Med 2010;363:245–56
  • Gadde KM , Allison DB , Ryan DH , Peterson CA , Troupin B , Schwiers ML , Day WW . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52
  • Press Announcements . FDA approves weight-management drug Saxenda [Internet]. 2015. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm
  • Press Announcements . FDA approves weight-management drug Contrave [Internet]. 2014. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm
  • European Medicines Agency . News and Events - Saxenda recommended for approval in weight management in adults [Internet]. 2015. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002255.jsp&mid=WC0b01ac058004d5c1
  • Ornellas T , Chavez B . Naltrexone SR/Bupropion SR (Contrave): A new approach to weight loss in obese adults. P T 2011;36:255–62
  • Greenway FL , Fujioka K , Plodkowski RA , Mudaliar S , Guttadauria M , Erickson J , et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605
  • Apovian CM , Aronne L , Rubino D , Still C , Wyatt H , Burns C , et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013;21:935–43
  • Hollander P , Gupta AK , Plodkowski R , Greenway F , Bays H , Burns C , et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type2 diabetes. Diabetes Care 2013;36:4022–9
  • Meeran K , O’Shea D , Edwards CM , Turton MD , Heath MM , Gunn I , et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999;140:244–50
  • Turton MD , O’Shea D , Gunn I , Beak SA , Edwards CM , Meeran K , et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72
  • Parker JA , McCullough KA , Field BC , Minnion JS , Martin NM , Ghatei MA , Bloom SR . Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obesity 2013;37:1391–8
  • Trujillo JM , Nuffer W , Ellis SL . GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19–28
  • Buse JB , Rosenstock J , Sesti G , Schmidt WE , Montanya E , Brett JH , et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
  • Wadden TA , Hollander P , Klein S , Niswender K , Woo V , Hale PM , et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obesity 2013;37:1443–51
  • Astrup A , Rössner S , Van Gaal L , Rissanen A , Niskanen L , Al Hakim M , et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–16
  • Astrup A , Carraro R , Finer N , Harper A , Kunesova M , Lean ME , et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obesity 2012;36:843–54
  • Ratner RE , Maggs D , Nielsen LL , Stonehouse AH , Poon T , Zhang B , et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes 2006;8:419–28
  • Elashoff M , Matveyenko A V , Gier B , Elashoff R , Butler PC . Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–6
  • Nauck MA . A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126–32
  • Nauck MA , Friedrich N . Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36:S245–52
  • Asakawa A , Inui A , Yuzuriha H , Ueno N , Katsuura G , Fujimiya M , et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124:1325–36
  • Batterham RL , Le Roux CW , Cohen MA , Park AJ , Ellis SM , Patterson M , et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989–92
  • Tan TM , Field BCT , Minnion JS , Cuenco-Shillito J , Chambers ES , Zac-Varghese S , et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012;73:232–9
  • Batterham RL , Cowley MA , Small CJ , Herzog H , Cohen MA , Dakin CL , et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–4
  • Tan TM , Field BCT , McCullough KA , Troke RC , Chambers ES , Salem V , et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013;62:1131–8
  • Schulman JL , Carleton JL , Whitney G , Whitehorn JC . Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957;11:419–21
  • Fosgerau K , Hoffmann T . Peptide therapeutics: Current status and future directions. Drug Discov Today 2015;20:122–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.